Lasa Supergenerics Ltd

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has scheduled a Board Meeting on November 14, 2026, to consider and approve unaudited financial results for the quarter and half year ended September 30, 2026.

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has submitted a certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, confirming the dematerialization of securities up to September 30, 2026.

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has announced the Scrutinizer report of its 11th Annual General Meeting (AGM) held on September 30, 2026, where all resolutions were approved by the members with requisite majority.

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd held its 11th Annual General Meeting (AGM) on September 30, 2026, through video conferencing. The meeting was attended by 34 members, and the requisite quorum was present. The Chairman, Dr. Omkar Herlekar, addressed the members and provided an overview of the company's operations and financial performance for the financial year ended March 31, 2026. The company also provided the facility for remote e-voting on all 7 items of business, and the voting results will be submitted to the stock exchange within the stipulated time.

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has closed its trading window for designated employees and their immediate relatives from October 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter and half year ended September 30, 2026.

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has appointed Mr. Janardan Savala as an Additional Director in the capacity of Executive Director, subject to approval from members at the ensuing General Meeting/Postal Ballot.

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has announced the resignation of Mr. Ganesh Potdar as Whole-time Director of the company, effective August 25, 2026, citing personal commitments.

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has submitted its integrated filing for the quarter ended June 30, 2026, along with unaudited financial results and a limited review report from its statutory auditor. The company's board of directors has approved the unaudited financial results and the limited review report. The auditor's report draws attention to an exceptional item, an uninsured loss due to a fire incident at the company's factory in May 2025.

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has announced its unaudited financial results for the quarter ended June 30, 2026, with the Board of Directors considering and approving the results. The company has also drawn attention to exceptional items, including a fire incident at its factory, resulting in a loss of Rs.2057.47 Lacs, and impairment of tangible assets.

Lasa Supergenerics Ltd

Lasa Supergenerics Ltd has scheduled a board meeting on August 14, 2026, to consider and approve unaudited financial results for the quarter ended June 30, 2026. The trading window remains closed till 48 hours after the declaration of results.